654 related articles for article (PubMed ID: 32330574)
1. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
[TBL] [Abstract][Full Text] [Related]
2. EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.
van Driel PBAA; Boonstra MC; Slooter MD; Heukers R; Stammes MA; Snoeks TJA; de Bruijn HS; van Diest PJ; Vahrmeijer AL; van Bergen En Henegouwen PMP; van de Velde CJH; Löwik CWGM; Robinson DJ; Oliveira S
J Control Release; 2016 May; 229():93-105. PubMed ID: 26988602
[TBL] [Abstract][Full Text] [Related]
3. Nanobody-photosensitizer conjugates for targeted photodynamic therapy.
Heukers R; van Bergen en Henegouwen PM; Oliveira S
Nanomedicine; 2014 Oct; 10(7):1441-51. PubMed ID: 24394212
[TBL] [Abstract][Full Text] [Related]
4. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
5. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
[TBL] [Abstract][Full Text] [Related]
6. Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging.
de Bruijn HS; Mashayekhi V; Schreurs TJL; van Driel PBAA; Strijkers GJ; van Diest PJ; Lowik CWGM; Seynhaeve ALB; Hagen TLMT; Prompers JJ; Henegouwen PMPVBE; Robinson DJ; Oliveira S
Theranostics; 2020; 10(5):2436-2452. PubMed ID: 32089747
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates.
Beltrán Hernández I; De Groof TWM; Heukers R; Oliveira S
Methods Mol Biol; 2022; 2451():505-520. PubMed ID: 35505028
[TBL] [Abstract][Full Text] [Related]
8. Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells.
De Groof TWM; Mashayekhi V; Fan TS; Bergkamp ND; Sastre Toraño J; van Senten JR; Heukers R; Smit MJ; Oliveira S
Mol Pharm; 2019 Jul; 16(7):3145-3156. PubMed ID: 31244224
[TBL] [Abstract][Full Text] [Related]
9. Orthotopic Breast Cancer Model to Investigate the Therapeutic Efficacy of Nanobody-Targeted Photodynamic Therapy.
Deken MM; Bhairosingh SS; Vahrmeijer AL; Oliveira S
Methods Mol Biol; 2022; 2451():547-556. PubMed ID: 35505031
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of [
Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
12. Measurement of Cyanine Dye Photobleaching in Photosensitizer Cyanine Dye Conjugates Could Help in Optimizing Light Dosimetry for Improved Photodynamic Therapy of Cancer.
James NS; Cheruku RR; Missert JR; Sunar U; Pandey RK
Molecules; 2018 Jul; 23(8):. PubMed ID: 30042350
[TBL] [Abstract][Full Text] [Related]
13. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates.
van Lith SAM; van den Brand D; Wallbrecher R; Wübbeke L; van Duijnhoven SMJ; Mäkinen PI; Hoogstad-van Evert JS; Massuger L; Ylä-Herttuala S; Brock R; Leenders WPJ
Eur J Pharm Biopharm; 2018 Mar; 124():63-72. PubMed ID: 29274374
[TBL] [Abstract][Full Text] [Related]
14. Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy.
Mashayekhi V; Xenaki KT; van Bergen En Henegouwen PMP; Oliveira S
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32977602
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer.
Yamashita S; Kojima M; Onda N; Yoshida T; Shibutani M
Cancer Med; 2023 Feb; 12(4):4579-4589. PubMed ID: 36259134
[TBL] [Abstract][Full Text] [Related]
16. A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells.
Liu X; Luan L; Liu X; Jiang D; Deng J; Xu J; Yuan Y; Xing J; Chen B; Xing D; Huang H
Front Immunol; 2023; 14():1292839. PubMed ID: 37954614
[TBL] [Abstract][Full Text] [Related]
17. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
[TBL] [Abstract][Full Text] [Related]
18. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
19. Nanobody-Targeted Photodynamic Therapy: Nanobody Production and Purification.
Mashayekhi V; Schooten E; van Bergen En Henegouwen PMP; Kijanka MM; Oliveira S
Methods Mol Biol; 2022; 2451():481-493. PubMed ID: 35505026
[TBL] [Abstract][Full Text] [Related]
20. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
